| Literature DB >> 25233127 |
Seung-In Choi1, Sungjae Yoo2, Ji Yeon Lim3, Sun Wook Hwang4.
Abstract
Oxidative stress induces numerous biological problems. Lipid oxidation and peroxidation appear to be important steps by which exposure to oxidative stress leads the body to a disease state. For its protection, the body has evolved to respond to and eliminate peroxidation products through the acquisition of binding proteins, reducing and conjugating enzymes, and excretion systems. During the past decade, researchers have identified a group of ion channel molecules that are activated by oxidized lipids: transient receptor potential (TRP) channels expressed in sensory neurons. These ion channels are fundamentally detectors and signal converters for body-damaging environments such as heat and cold temperatures, mechanical attacks, and potentially toxic substances. When messages initiated by TRP activation arrive at the brain, we perceive pain, which results in our preparing defensive responses. Excessive activation of the sensory neuronal TRP channels upon prolonged stimulations sometimes deteriorates the inflammatory state of damaged tissues by promoting neuropeptide release from expresser neurons. These same paradigms may also work for pathologic changes in the internal lipid environment upon exposure to oxidative stress. Here, we provide an overview of the role of TRP channels and oxidized lipid connections during abnormally increased oxidative signaling, and consider the sensory mechanism of TRP detection as an alert system.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25233127 PMCID: PMC4200803 DOI: 10.3390/ijms150916430
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Transient receptor potential (TRP)A1 topology highlighting key domains, phosphorylation sites, and ligand binding pockets that affect gating functions. Abbreviations: TM, transmembrane domain; LPO, lipid peroxidation; ANK, ankyrin repeat; CaM binding, calmodulin binding site; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, substrate regions for protein kinase C actions; TRP box, conserved amino acids in TRPA, TRPC, TRPV, and TRPM subfamilies; Voltage, predicted voltage-sensing domain.
Figure 2TRPV1 topology highlighting key domains, phosphorylation sites, and ligand binding pockets that affect gating functions. Abbreviations: H+, proton binding site; TM, transmembrane domain; CAP, capsaicin binding region; PKC, substrate regions for protein kinase C actions; PKA, substrate regions for protein kinase A actions; CaMKII, substrate regions for Ca2+/calmodulin-dependent protein kinase action; Voltage, predicted voltage-sensing domain; TRP box, conserved amino acids in TRPA, TRPC, TRPV, and TRPM subfamilies; CaM binding, calmodulin binding site; LPA, lysophosphatidic acid binding site; PIP2, phosphatidylinositol 4,5-bisphosphate.
Figure 3Lipid hydroperoxides (LOX metabolites).
List of the lipid peroxidation (LPO) products that activate sensory transient receptor potential (TRP) channels.
| LPO Categories | Oxidized or Peroxidized Lipids | Target TRPs, EC50s, and References |
|---|---|---|
| Lipid hydroperoxides (LOX metabolites) | 12(
| TRPA1 |
| HpETEs and HpODEs (not tested) | ||
| 9(
| ||
| 13(
| ||
| TRPV1 | ||
| 12(
| ||
| 15(
| ||
| 9(
| ||
| 13(
| ||
| Cf. related HODE metabolites | ||
| 9(
| ||
| 13(
| ||
| HpODEs | ||
| Not tested | ||
| Isoprostanes | 8-iso PGA1 | TRPA1 |
| 8-iso PGA2 (22.4 μM (in murine DRG (mDRG)), [ | ||
| Cf. related cyclopentanone PGs: | ||
| PGA1 (15.1 μM {mDRG}, [ | ||
| PGA2 (24 μM {mDRG}, [ | ||
| ∆12-PGJ2 (10–100 μM, [ | ||
| 15d-PGJ2 (5.6 μM, [ | ||
| TRPV1 | ||
| 8-iso PGA2 (no effect {mDRG}, [ | ||
| 8-iso PGA1 & J-series isoprostanes | ||
| Not tested | ||
| Acrolein and its analogs | Acrolein | TRPA1 |
| Acrolein (5 μM, [ | ||
| Crotonaldehyde (23 μM, [ | ||
| Pentenal (5 μM, [ | ||
| Hexenal (~10 μM, [ | ||
| TRPV1 | ||
| Acrolein (no effect, [ | ||
| Crontonaldehyde (no effect, [ | ||
| Pentenal (no effect, [ | ||
| Hexenal (no effect, [ | ||
| 4-HNE and related alkenals | 4-HNE | TRPA1 |
| 4-HNE (13 μM, [ | ||
| 4-HHE (38.9 μM, [ | ||
| 4-ONE (1.9 μM, [ | ||
| TRPV1 | ||
| 4-HNE (no effect, [ | ||
| 4-HHE (not tested) | ||
| 4-ONE (≥100 μM, [ | ||
| 4-HDDE/4-HPNE/4-HPHE | ||
| Not tested | ||
| α-Oxoaldehydes | Glyoxal | TRPA1 |
| Glyoxal (no effect, [ | ||
| Methylglyoxal (0.59 μM (β-cell), [ | ||
| TRPV1 | ||
| Glyoxal (not tested) | ||
| Methylglyoxal (no effect, [ | ||
| Components of oxidized LDLs | Hexanal | TRPA1 |
| Pentanal/hexanal (not tested) | ||
| TRPV1 | ||
| Pentanal/hexanal (not tested) | ||
| LPC (not tested) | ||
| Pentanal on native neurons | ||
| An unknown target (1–10 mM? on rat trigeminal neurons, [ | ||
| LPC | ||
| TRPM8 (~10 μM, [ | ||
| Cf. related substances | ||
| Formaldehyde (200–400 μM, [ | ||
| Acetaldehyde (76.5–1190 μM, [ | ||
| Malondialdehyde | Malondialdehyde | Not tested |
TRPA1 and TRPV1, namely pain-mediating TRP channels; HpETEs, hydroperoxyeicosatetraenoic acids; HODEs, hydroxyoctadecadienoic acids; HpODEs, hydroperoxyoctadecadienoic acids; 4-HNE, 4-hydroxy-2-nonenal; 4-HHE, 4-hydroxy-2-hexenal; 4-ONE, 4-oxo-2-nonenal; 4-HDDE, 4-Hydroxy-2,6-dodecadienal; 4-HPNE, 4-hydroperoxy-2-nonenal; 4-HPHE, 4-hydroperoxy-2-hexenal; LDL, Low-density lipoprotein; LPC, Lysophosphatidylcholine; PG, prostaglandin.
Figure 4Isoprostanes.
Figure 5Acrolein and its analogs.
Figure 6Hydroxy-2-nonenal (HNE) and related alkenals.
Figure 7α-Oxoaldehydes, alkanals, and LPC.